HC Wainwright reissued their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a report released on Tuesday,Benzinga reports. They currently have a $40.00 price target on the stock.
A number of other equities research analysts have also recently commented on JSPR. UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective on the stock. JMP Securities restated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a report on Thursday, January 9th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $63.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics has an average rating of "Buy" and an average price target of $62.50.
Get Our Latest Analysis on JSPR
Jasper Therapeutics Trading Up 2.0 %
Shares of NASDAQ:JSPR traded up $0.11 on Tuesday, reaching $5.49. 153,170 shares of the company were exchanged, compared to its average volume of 267,785. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The firm has a market cap of $82.47 million, a price-to-earnings ratio of -1.16 and a beta of 2.23. The company has a 50-day moving average of $6.72 and a 200-day moving average of $15.94.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). As a group, analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of JSPR. Braidwell LP purchased a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $9,091,000. Boxer Capital Management LLC acquired a new stake in Jasper Therapeutics during the 4th quarter worth approximately $7,483,000. Integral Health Asset Management LLC increased its position in Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock worth $13,897,000 after purchasing an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC increased its position in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its position in Jasper Therapeutics by 11.2% during the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock worth $31,951,000 after purchasing an additional 150,755 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Articles
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
